News stories about Viking Therapeutics (NASDAQ:VKTX) have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Viking Therapeutics earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.6180286271656 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have effected Accern Sentiment’s rankings:
- May This Data Fuel Up Investor’s Confidence – Viking Therapeutics … – Stock Trading Point (press release) (stocktradingpoint.com)
- Trending Shares: Viking Therapeutics, Inc. (VKTX) stock price settles at $5.33 with movement of -1.30% – Nasdaq Express (nasdaqexpress.com)
- Evaluate Stock’s Volatility Before Making Any Investment Decision … – Stock Watch (stocksnewstimes.com)
- Intraday Trade Secrets – Viking Therapeutics Inc (NASDAQ: VKTX) – Alpha Beta Stock (alphabetastock.com)
- RSI Alert – Viking Therapeutics, Inc. (NASDAQ: VKTX) – The Investor Guide (wallstreetnews24.com)
VKTX stock traded down $0.44 during trading on Friday, hitting $4.61. The company’s stock had a trading volume of 2,172,481 shares, compared to its average volume of 1,106,907. The company has a market cap of $257.04, a P/E ratio of -5.76 and a beta of 1.81. Viking Therapeutics has a 1-year low of $0.88 and a 1-year high of $7.36.
A number of equities research analysts have issued reports on the company. BidaskClub upgraded Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 7th. Maxim Group restated a “buy” rating and set a $8.00 price target on shares of Viking Therapeutics in a research note on Friday, February 2nd. Roth Capital set a $8.00 price target on Viking Therapeutics and gave the company a “buy” rating in a research note on Thursday, March 8th. Finally, ValuEngine downgraded Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Viking Therapeutics presently has an average rating of “Hold” and an average target price of $7.67.
ILLEGAL ACTIVITY NOTICE: “Viking Therapeutics (VKTX) Receives Daily Media Sentiment Rating of 0.11” was posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3296601/viking-therapeutics-vktx-receives-daily-media-sentiment-rating-of-0-11.html.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.